Pancreatic Cancer Research

ResearcherLyon 1 UniversitéActive in the last 2 years

Mustapha Adham

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4371-7365; OpenAlex author ID A5106323526, A5110076646. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
90
Papers, trials and grants by year

2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 20

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. First author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Aborted pancreatoduodenectomy after extensive vascular dissection in patients with pancreatic cancer: a word of caution. Co-author DOI 10.1007/s00464-024-11073-6↗
  3. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrad125↗
  4. Necrosis as a strong independent prognostic factor required in the implementation of pathological reporting for pancreatic adenocarcinoma resection specimens. Co-author DOI 10.1016/j.prp.2023.154406↗
  5. Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort. Co-author DOI 10.3390/cancers14215413↗
  6. Acute Pancreatitis as the Initial Presentation of Pancreatic Adenocarcinoma does not Impact Short- and Long-term Outcomes of Curative Intent Surgery: A Study o… Co-author DOI 10.1007/s00268-021-06205-1↗
  7. Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database. First author DOI 10.3390/cancers13143515↗
  8. Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Co-author DOI 10.1038/s41419-020-2262-1↗
  9. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Co-author DOI 10.1016/j.ejso.2018.12.012↗
  10. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Co-author DOI 10.1038/s41419-019-2116-x↗
  11. Palliative therapy in pancreatic cancer-palliative surgery. First author DOI 10.21037/tgh.2019.04.03↗
  12. An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jgo.2018.03.007↗
  13. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  14. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  15. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment?… Co-author DOI 10.1016/j.ejso.2017.06.011↗
  16. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicent… Co-author DOI 10.1016/j.surg.2016.02.019↗
  17. Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2015.03.058↗
  18. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  19. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.009↗
  20. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic … Co-author DOI 10.1016/j.surg.2014.06.016↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julie Périnel · 8 shared papers, 2016–2024 · strength 0.92
  2. Valérie Hervieu · 4 shared papers, 2019–2023 · strength 0.44
  3. Tanguy Fenouil · 3 shared papers, 2019–2023 · strength 0.35
  4. Alain Sauvanet Sauvanet · 5 shared papers, 2015–2021 · strength 0.34
  5. Claudio Bassi · 6 shared papers, 2014–2019 · strength 0.27
  6. Mircea Chirica · 1 shared paper, 2024 · strength 0.24
  7. Quentin Chenevas-Paule · 1 shared paper, 2024 · strength 0.24
  8. Jean‐Robert Delpéro · 3 shared papers, 2015–2021 · strength 0.23
  9. François Paye · 3 shared papers, 2015–2021 · strength 0.23
  10. Philippe Bachellier · 3 shared papers, 2015–2021 · strength 0.23
  11. Jakob Robert Izbicki · 5 shared papers, 2014–2019 · strength 0.22
  12. Helmut Friess · 2 shared papers, 2014–2024 · strength 0.22
  13. Christelle de la Fouchardière · 2 shared papers, 2021–2022 · strength 0.22
  14. Nicolas Williet · 2 shared papers, 2021–2022 · strength 0.22
  15. Maximilian Bockhorn · 4 shared papers, 2014–2019 · strength 0.19
  16. Rüdiger Göß · 1 shared paper, 2024 · strength 0.18
  17. Alexander Muckenhuber · 1 shared paper, 2024 · strength 0.18
  18. Ilaria Pergolini · 1 shared paper, 2024 · strength 0.18
  19. Stephan Schorn · 1 shared paper, 2024 · strength 0.18
  20. Florian Scheufele · 1 shared paper, 2024 · strength 0.18
  21. Alexander Novotny · 1 shared paper, 2024 · strength 0.18
  22. Okan Safak · 1 shared paper, 2024 · strength 0.18
  23. İhsan Ekin Demir · 1 shared paper, 2024 · strength 0.18
  24. Guralp Onur Ceyhan · 1 shared paper, 2024 · strength 0.18
  25. Roberto Salvia · 3 shared papers, 2018–2019 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.